Robot Mediated Therapy-Upper Limb Outcomes in Stroke

March 28, 2023 updated by: Changi General Hospital

Effects of Robot-mediated Impairment-Oriented and Task-Specific Training on Upper Limb Outcomes Post Stroke (RMT-Stroke Outcomes)

This study aims to determine the clinical outcomes of stroke patients who are provided with adjunctive robot-mediated task specific therapy(RMTT) and robot-mediated impairment training (RMIT) as compared to those who are provided with adjunctive RMIT.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Stroke is among the top 10 causes of hospitalisation in Singapore1. Approximately 630 stroke patients were transferred to our inpatient rehabilitation unit in 2021. Upper limb impairments are common after stroke2 and may result in loss of function, including self-care activities. Intensity of therapy is thus important for post-stroke recovery. A Cochrane overview of systematic reviews suggested that arm function can be improved by providing at least 20 hours of additional repetitive task training to patients3. However, providing sufficient therapy remains a challenge due to various reasons4, including manpower shortages. Robotic-mediated rehabilitation is an innovative exercise-based therapy using robotic devices that enables the implementation of highly repetitive, intensive, adaptive, and quantifiable physical training.

The RATULS trial5 showed that neither robot-assisted training using the MIT-Manus robotic gym nor an enhanced upper limb therapy (EULT) programme based on repetitive functional task practice improved upper limb function after stroke, as compared to usual care, for patients with moderate-to-severe upper limb functional limitations. It was suggested that further research was needed to find ways to translate the improvements in upper limb impairments seen with robot-assisted therapy into upper limb function and their activities of daily living (ADLs).

In a systematic review and meta-analysis on the effects of robot-assisted therapy on the upper limb, it was found that although there were improvements in strength, this was not translated to improvements in activities of daily living6. Additional transition to task training (facilitated by therapists) had been added to robot-mediated impairment training (RMIT) in various studies7,8. In a study by Hung8, robot-assisted therapy combined with occupational therapist (OT)-facilitated task specific training was found to be superior to robot-assisted therapy combined with OT-facilitated impairment-oriented training. Task-specific training consists of repetitively practising the tasks that are most relevant to the patient and their personal context, whereas impairment-oriented therapy emphasises remediation of motor deficits with a focus on single joint movements at a time.

A study that investigated Reharob, a robotic device used to assist patients living with chronic stroke in performing 5 ADLs, showed that patients had significant improvements on the Fugl-Meyer Assessment - Upper Extremity (FMA-UE), Action Research Arm Test (ARAT) and Functional Independence Measure (FIM)9. This is the only study that has been found addressing robot-mediated task-specific training thus far (RMTT).

This study aims to determine the clinical outcomes of stroke patients who are provided with both RMTT and robot-mediated impairment training (RMIT) in addition to conventional therapy, as compared to those who are provided with only adjunctive RMIT. From a review of the prevalent literature, there has been no study on the comparison of RMTT + RMIT against RMIT alone. A search for RMTT only yielded the study on Reharob, but the robot only administered RMTT and not RMIT.

The target patients would be those with acute stroke undergoing rehabilitation in an acute inpatient rehabilitation unit. Robotic therapy can continue when they are discharged, in the outpatient setting.

Study Type

Interventional

Enrollment (Anticipated)

96

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnosis of stroke as evidenced by CT/MRI findings
  2. First-ever stroke (ischaemic or haemorrhagic)
  3. Upper limb weakness and an FMA-UE score of 16-53 (severe to moderate: 16-34. moderate to mild: 35-53)12,13
  4. Cognitively intact to follow instructions
  5. Medically stable to participate
  6. Consent given
  7. Age 21 and above

Exclusion Criteria:

1. Fractures or other musculoskeletal issues that render the use of the robotic device unsuitable 2. Involvement in another concurrent upper limb study 3. Wounds that do not allow donning of the device 4. Severe spasticity 5. Cognitive impairment (MMSE ≤20) 6. Inability to follow instructions 7. Severe osteoporosis 8. Infectious diseases that require the patient to be isolated in a single room eg airborne diseases

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Robot mediated Impairment-oriented training(RMIT)
Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen

The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then "replaying" the movement at either zero, partial or full assistance for the patient.

Impairment oriented training will focus on the following movements:

  1. Diagonal movement
  2. Shoulder abduction
  3. Shoulder adduction
  4. Shoulder flexion
  5. Shoulder extension
  6. Elbow flexion
  7. Elbow extension

Task-specific training will focus on the following activities:

  1. Picking up a cup/glass by the side and drink
  2. Brushing hair
  3. Cleaning unaffected upper limb (hand to arm)
  4. Wiping table
  5. Wiping wall
  6. Sliding card on table to a designated location
  7. Clipping a clothe peg
Experimental: Robot mediated impairment-oriented and task-specific training (RMIT+RMTT)
Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT

The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then "replaying" the movement at either zero, partial or full assistance for the patient.

Impairment oriented training will focus on the following movements:

  1. Diagonal movement
  2. Shoulder abduction
  3. Shoulder adduction
  4. Shoulder flexion
  5. Shoulder extension
  6. Elbow flexion
  7. Elbow extension

Task-specific training will focus on the following activities:

  1. Picking up a cup/glass by the side and drink
  2. Brushing hair
  3. Cleaning unaffected upper limb (hand to arm)
  4. Wiping table
  5. Wiping wall
  6. Sliding card on table to a designated location
  7. Clipping a clothe peg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of FMA-UE(Fugl Meyer Assessment for Upper Extremity) from baseline
Time Frame: baseline, 1 month and 3 months post commencement of intervention
30 items assessing motor function and 3 items assessing reflex function (0-66, higher scores indicates better outcomes)
baseline, 1 month and 3 months post commencement of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of FMA-UA( Fugl Meyer Assessment-Upper Arm) from baseline
Time Frame: baseline, 1 month and 3 months post commencement of intervention
subset of FMA-UE( 0-36, higher score indicates better outcomes)
baseline, 1 month and 3 months post commencement of intervention
Change of FMA-W/H (Fugl Meyer Assessment- Wrist/Hand) from baseline
Time Frame: baseline, 1 month and 3 months post commencement of intervention
subset of FMA-UE (0-30, higher scores indicates better outcomes)
baseline, 1 month and 3 months post commencement of intervention
Change of FAT( Frenchay Arm Test) from baseline
Time Frame: baseline, 1 month and 3 months post baseline
Upper limb functional assessment (0-5, higher score indicates better outcomes)
baseline, 1 month and 3 months post baseline
Change of FIM (Functional Independence Measure) from baseline
Time Frame: baseline, 1 month, 3 months post baseline
Functional outcome measure, mainly used in inpatient setting (18-126, higher score indicates better outcomes)
baseline, 1 month, 3 months post baseline
Change of MMT( manual muscle testing) from baseline
Time Frame: baseline, 1 month and 3 months post baseline
Using the Medical Research Council scale (0-5, higher indicates better outcomes)
baseline, 1 month and 3 months post baseline
Change of MAS (Modified Ashworth Scale) from baseline
Time Frame: baseline, 1 month and 3 months post baseline
spasticity assessment scale (0-4, lower indicates better outcomes)
baseline, 1 month and 3 months post baseline
Change of EQ5D from baseline
Time Frame: baseline, 1 month and 3 months post baseline
Quality of Life Questionaire (0-100, higher score indicates better outcomes)
baseline, 1 month and 3 months post baseline
Change of HADS (Hospital Anxiety and Depression Scale) from baseline
Time Frame: baseline, 1 month and 3 months post baseline
Masurement of mood (0-42, more than 8 points in each subcategory indicates considerable symptoms of anxiety or depression)
baseline, 1 month and 3 months post baseline
Change of patient satisfaction survey from baseline
Time Frame: baseline, 1 month and 3 months post baseline
Patient satisfaction survey (8-40), higher score denotes good outcome)
baseline, 1 month and 3 months post baseline
Difference in the presence of adverse effects
Time Frame: baseline, 1 month and 3 months post baseline
fatigue, pain, injuries (present or absent. Absent denotes better outcome)
baseline, 1 month and 3 months post baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2023

Primary Completion (Anticipated)

May 31, 2025

Study Completion (Anticipated)

December 31, 2025

Study Registration Dates

First Submitted

March 28, 2023

First Submitted That Met QC Criteria

March 28, 2023

First Posted (Actual)

April 10, 2023

Study Record Updates

Last Update Posted (Actual)

April 10, 2023

Last Update Submitted That Met QC Criteria

March 28, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke, Acute

Clinical Trials on Robot mediated upper limb therapy

3
Subscribe